Rewiring antitumor immunity: targeting CLDN18.2 with conditional 4-1BB activation.

IF 10.2 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2025-09-29 DOI:10.1158/1078-0432.ccr-25-2554

Giulia Pretelli,Elena Garralda

引用次数: 0

Abstract

Claudin 18.2 has emerged as a validated target in solid tumors, spurring next-generation therapies. Bispecific antibodies linking Claudin 18.2 to conditional 4-1BB activation offer a novel approach to enhance T cell function. By confining co-stimulation to the tumor microenvironment, they aim to boost efficacy while limiting systemic toxicity.

查看原文本刊更多论文

重新布线抗肿瘤免疫：靶向CLDN18.2条件4-1BB激活。

Claudin 18.2已成为实体肿瘤的有效靶点，刺激了下一代治疗。将Claudin 18.2连接到条件4-1BB激活的双特异性抗体提供了一种增强T细胞功能的新方法。通过将共刺激限制在肿瘤微环境中，他们旨在提高疗效，同时限制全身毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.